In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results